TITLE: Recombinant Human Thrombin: Clinical Effectiveness And Cost-Effectiveness
|
|
- Julian Lyons
- 5 years ago
- Views:
Transcription
1 TITLE: Recombinant Human Thrombin: Clinical Effectiveness And Cost-Effectiveness DATE: 08 November 2010 CONTEXT AND POLICY ISSUES: Excessive bleeding during surgical procedures can lead to increased morbidity and mortality. Thrombin has been long used in surgery as an aid for achieving operative hemostasis. 1 Until recently, most of the thrombin used as topical agent was derived from bovine plasma. 2 There are concerns about the safety of bovine thrombin (bthrombin) as some patients treated with bthrombin developed antibodies against bovine coagulation factors. 2 These patients would be at high risk of immune reaction when re-exposed to bthrombin. 2 The search for an alternative product lead to the recent development of a recombinant human thrombin (rhthrombin), and Phase II and III clinical trials have recently been completed. 3 This report reviews the evidence of clinical effectiveness and cost-effectiveness of rhthrombin used as topical agent to achieve surgical hemostasis. RESEARCH QUESTIONS: 1. What is the clinical effectiveness of using rhthrombin for hemostasis? 2. What is the safety of using rhthrombin for hemostasis? 3. What is the cost effectiveness of using rhthrombin for hemostasis? KEY MESSAGE: Limited clinical evidence suggests that the use of rhthrombin as an aid to hemostasis is effective and safe during surgery and at one-month follow-up. Disclaimer: The Health Technology Inquiry Service (HTIS) is an information service for those involved in planning and providing health care in Canada. HTIS responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. HTIS responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material. It may be copied and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners own terms and conditions.
2 METHODS: A limited literature search was conducted on key health technology assessment resources, including PubMed, OVID EMBASE, the Cochrane Library (Issue 10, 2010), University of York Centre for Reviews and Dissemination (CRD) databases, ECRI (Health Devices Gold), EuroScan, international health technology agencies, and a focused Internet search. The search was limited to English language articles published between January 1, 2005 and October 6, Filters were applied to limit the retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials and economic studies. A non-randomized studies filter was applied to a focused search (omitting thrombin name variants) for targeted non-randomized studies. SUMMARY OF FINDINGS: The literature search identified one phase II randomized controlled trial (RCT), 4 one phase III RCT reported in two published articles, 5,6 and two observational studies. 7,8 No systematic review/meta-analysis, economic studies or studies with cost information were identified. The characteristics of the included studies and the efficacy and safety of rhthrombin are presented in Appendices 1 and 2, respectively. Randomized controlled trials A phase II, multicentre, double-blind, randomized controlled trial 4 evaluated the safety of rhthrombin as a topical hemostatic agent in 130 patients in four surgical settings (25% AV grafts placed, 22% liver resection, 21% peripheral arterial by-pass, and 32% spinal surgery). The treatment group received rhthrombin (1,000 IU/ml) while the control group received placebo only. The study was funded by ZymoGenetics. The authors reported that all the adverse events reported by the patients were not related to the study treatment. Compared to placebo, patients receiving rhthrombin had higher incidence of nausea (45% vs. 26%), constipation (27% vs. 12%), insomnia (19% vs. 5%), and vomiting (13% vs. 2%). The incidence of serious adverse events was 19% in the placebo group and 24% in the rhthrombin group. One patient in each group died while undergoing hepatic resections. Both groups had similar proportions of patients having preexisting antibodies (4.8% placebo, 5.6% rhthrombin). Each group had one patient who developed antibodies to rhthrombin while on the study. No statistical analysis was done for any of the comparisons. The authors concluded that rhthrombin appears to be safe in different surgical settings. A phase III, multicentre, double-blind, randomized controlled trial 5 evaluated the efficacy and safety of rhthrombin used as topical agent to the bleeding site in 411 adult patients undergoing various types of surgery including liver resection (30%), spinal surgery (30%), peripheral arterial by-pass (21%) and dialysis access surgery (19%). The treatment group received rhthrombin (1,000 IU/ml) while the control group received bthrombin (1,000 IU/ml). The study was funded by ZymoGenetics. Primary efficacy end-point was time to hemostasis, summarized as incidence of hemostasis within 10 minutes. The results showed that both agents had comparable efficacy, with 95% of the patients in each group achieving hemostasis within 10 minutes. The common adverse events were as expected after operation and were similar between treatment groups. They included incision site complication, nausea, procedural pain, constipation, pyrexia, vomiting, Recombinant human thrombin 2
3 peripheral edema, anemia, hypokalemia and insomnia. Development of antibodies detected at end of study (one month) was significantly higher in the bthrombin group than in the rhthrombin group (21.5% vs. 1.5%, p<0.0001). The authors concluded that rhthrombin has similar efficacy and safety profile, but is less immunogenic than bthrombin when used as an aid for surgical hemostasis. A sub-group study 6 of the above trial reported the efficacy and safety of rhthrombin used in 164 patients undergoing vascular surgery. In this sub-population, both rhthrombin and bthrombin also showed similar efficacy (91% vs. 94%, p=0.28) and safety profile. More patients in the bthrombin group developed antibodies compared to the rhthrombin group (27% vs. 0%, p<0.0001). It was concluded that both agents were similarly well-tolerated, and rhthrombin was less immunogenic than bthrombin. Observational studies Two multicentre, single arm, open-label studies were identified. One study 7 evaluated the safety and immunogenicity of rhthrombin on patients (N=72) undergoing burn wound excision and grafting, and the other study 8 on patients (N=209) undergoing vascular and spinal surgery. A significant proportion of patients (15.5%) in the second study 8 had anti-bthrombin antibodies at baseline. Both studies were funded by ZymoGenetics. Development of anti-rhthrombin antibodies was found in 1.6% of patients (1/62) in first study 7 and in 0% of patients (0/200) in the second study. 8 Most patients in both studies had adverse events as expected after surgery. Common adverse events included incision site pain, procedural pain, nausea, constipation, anemia, muscle spasms and hypotension. Both studies concluded that the rhthrombin was well tolerated when used as an aid to hemostasis in respective surgical procedure. Limitations The evidence was limited in that only one phase II RCT, one phase III RCT and two observational studies were identified. Safety profile beyond day 30 after operation was unknown. All of the identified studies were funded by pharmaceutical industry, ZymoGenetics. CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING: rhthrombin was found to be as effective as bthrombin. The complications were those as expected after a surgical procedure. Development of immunogenicity at study end (day 29) was significantly lower with rhthrombin than with bthrombin. However, giving the limitation of the clinical evidence and the lack of cost data, the advantage of rhthrombin over bthrombin is uncertain. PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: Recombinant human thrombin 3
4 REFERENCES: 1. Anderson CD, Bowman LJ, Chapman WC. Topical use of recombinant human thrombin for operative hemostasis. Expert Opin Biol Ther Jan;9(1): Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost Jul;102(1): Ballard JL, Weaver FA, Singla NK, Chapman WC, Alexander WA. Safety and immunogenicity observations pooled from eight clinical trials of recombinant human thrombin. J Am Coll Surg Feb;210(2): Chapman WC, Lockstadt H, Singla N, Kafie FE, Lawson JH. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost [Internet] [cited 2010 Oct 7];4(9): Available from: 5. Chapman WC, Singla N, Genyk Y, McNeil JW, Renkens KL, Reynolds TC, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg Aug;205(2): Weaver FA, Lew W, Granke K, Yonehiro L, Delange B, Alexander WA, et al. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg Jun;47(6): Greenhalgh DG, Gamelli RL, Collins J, Sood R, Mozingo DW, Gray TE, et al. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting. J Burn Care Res May;30(3): Singla NK, Ballard JL, Moneta G, Randleman CD, Renkens KL, Alexander WA. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis. J Am Coll Surg Jul;209(1): Recombinant human thrombin 4
5 APPENDICES: Appendix 1: Characteristics of included studies Author Design Population Treatment arm(s) Control arm Co-intervention Follow-up 42 patients receiving NR NR (2006) 4 Multicentre, doubleblind, randomized, two parallel groups placebo (2007) 5 Weaver et al. (2008) 6 [Sub-group study of (2007) 5 ] Multicentre, doubleblind, randomized, two parallel groups Multicentre, doubleblind, randomized, two parallel groups 130 patients (age, NR) undergoing surgery (dialysis access surgery (20%), liver resection (22%), spine (32%), peripheral arterial bypass (21%)) 411 patients (age years) undergoing surgery (liver resection (30%), spine (30%), peripheral arterial bypass (21%), dialysis access surgery (19%)) 164 patients (age years) undergoing vascular surgery 88 patients receiving rht (1,000 IU/ml) as topical agent to bleeding site 205 patients receiving rht (1,000 IU/ml) as topical agent to bleeding site 82 patients receiving rht (1,000 IU/ml) as topical agent to bleeding site 206 patients receiving bt (1,000 IU/ml) as topical agent to bleeding site 82 patients receiving bt (1,000 U/ml) as topical agent to bleeding site Absorbable gelatin sponge; gauze pad Hold pad in place with gentle pressure and change at least every 30 seconds until hemostasis achieved Absorbable gelatin sponge; gauze pad Hold pad in place with gentle pressure and change at least every 30 seconds until hemostasis achieved 1 month after operation 1 month after operation Greenhalgh et al. (2009) 7 Singla et al. (2009) 8 Multicentre, single arm, open-label Multicentre, single arm, open-label 72 patients (age 12 to 70 years) with acute burns, who were receiving partial- or fullthickness autologous skin grafts 209 patients (mean age 61.5 years) 72 patients receiving rht (1,000 IU/ml) through a spray applicator 209 patients receiving rht (1,000 N/A Graft type: mesh grafts (25%); sheet graft (75%) 29 days after operation N/A Not mentioned 16 to 48 hours after surgery; and day 29 Recombinant Human Thrombin 5
6 Author Design Population Treatment arm(s) Control arm Co-intervention Follow-up undergoing vascular and spinal surgery, and 15.5% being at high risk for preexisting antibthrombin antibodies IU/ml) during surgical procedure as an aid to hemoatasis after surgery bt : bovine Thrombin; IU: international unit; N/A: not applicable; NR: not reported; rht : recombinant human thrombin Appendix 2: Efficacy and safety of recombinant human thrombin Author Patients completed / Efficacy (Incidence of hemostasis within 10 min) discontinued Absolute Difference Adverse events NR NR All patients (2006) 4 rht: 83 / 88 Pla: 41 / 42 reported at least one AE. None of the AE was considered to be related to (2007) 5 Weaver et al. (2008) 6 [Sub-group study of (2007) 5 ] rht: 201 / 4 bt: 200 / 6 rht: 80 / 2 bt: 81 / 1 rht: 95.4% bt: 95.1% rht: 91% bt: 94% Range from -0.7% (95% CI: -16.0, 14.6) in peripheral arterial bypass surgery to 1.6% (95% CI: -3.78, 6.91) in hepatic surgery No significant difference (data not shown) study treatment All patients reported at least one AE. None of the AE was considered to be related to study treatment Severity and specific AE: similar between treatment groups Similar between rht and bt groups for hemorrhagic (20% vs. 21%), cardiac (15% vs. 13%), Safety Immunogenicity at study end rht: 1.2% Pla: 2.4% rht: 1.5% bt: 21.5%, p< rht: 0% bt: 27%, p< Conclusion rhthrombin appears tp be safe in multiple surgical settings and did not provoke a clinically significant immune response rhthrombin has comparable efficacy, a similar safety profile, and is considerably less immunogenic than bthrombin when used for surgical hemostasis In patients undergoing vascular surgery, both treatments were similarly well tolerated, although rhthrombin demonstrated a superior immunogenicity profile Recombinant Human Thrombin 6
7 Author Greenhalgh et al. (2009) 7 Singla et al. (2009) 8 Patients completed / discontinued 71 patients evaluated for efficacy; 72 for safety 206 patients completed study; 200 patients were available for immunogenicity; 197 patients experienced AE Efficacy (Incidence of Safety hemostasis within 10 min) Absolute Difference Adverse Immunogenicity events at study end hypersensitivity (11% vs. 11%), thromboembolic (9% vs. 9%) Hemostasis at N/A Any AE: 88% 20 minutes Procedural pain: 1/62 (1.6%) rht: 91.5% 35% Skin graft failure: 6% N/A N/A Any AE: 94% Procedural pain: 39% Nausea: 27% Two deaths related to comorbidities 0/200 (0%) AE: adverse event; Ab: antibody; bt: bovine thrombin; IU: international unit; N/A: not applicable; NR: not reported; Pla: placebo; rht : recombinant human thrombin Conclusion rhthrombin was well tolerated when administered with a pump spray in patients undergoing skin grafting for burns rhthrombin can be used safely as an aid to hemostasis in patients with or without preexisting anti-bovine thrombin antibodies Recombinant Human Thrombin 7
THROMBIN-JMI (Thrombin, Topical (Bovine) U.S.P.), Solution for topical use Initial U.S. Approval: 1986
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use THROMBIN-JMI safely and effectively. See full prescribing information for THROMBIN-JMI. THROMBIN-JMI
More informationBevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW Introduction Brand name: Bevyxxa Generic name: Betrixaban Pharmacological class: Factor Xa inhibitor Strength and Formulation: 40mg, 80mg; caps Manufacturer:
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationPublished on The YODA Project (
Principal Investigator First Name: Mirjana Last Name: Stanic Benic Degree: MD Primary Affiliation: UHC Rijeka E-mail: mirji.stanic@gmail.com Phone number: 00385992367664 Address: Kresimirova 42e Kresimirova
More informationEach 7.0 cm x 7.0 cm dressing contains 140 to 260 mg of human fibrinogen and 130 International Units of human thrombin.
SurgiClot Hemostatic Dressing St. Teresa Medical, Inc. 2915 Waters Road, Suite 108 Eagan, Minnesota 55121 USA Tel: 651-789-6550 www.stteresamedical.com INSTRUCTIONS FOR USE DEVICE DESCRIPTION Each SurgiClot
More informationBAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING
FOR IMMEDIATE RELEASE Media Contact Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS
More informationThe Clinical Use and Immunologic Impact of Thrombin in Surgery
The Clinical Use and Immunologic Impact of Thrombin in Surgery Jeffrey H. Lawson, M.D., Ph.D. Departments of Surgery and Pathology Duke University Medical Center Durham, North Carolina Bovine Thrombin
More informationSurgical Adhesives in Facial Plastic Surgery
Surgical Adhesives in Facial Plastic Surgery Dean M. Toriumi, Victor K. Chung, Quintin M. Cappelle University of Illinois at Chicago Chicago, IL Supplement to Toriumi DM, Chung VK, Cappelle QM. Surgical
More informationBAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS
FOR IMMEDIATE RELEASE Media Contact: Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact: Clare Trachtman, (224) 948-3085 BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL
More information1. TITLE PAGE Study Title:
1. TITLE PAGE Study Title: A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada) Indication: Venous Thromboembolic Events Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationARTISS PROVIDES TIME FOR THE FINISHING TOUCH. [Solutions for Sealant] Application and Benefi ts in Burn Surgery
PROVIDES TIME FOR THE FINISHING TOUCH Full surface adherence eliminating dead space 3 Application and Benefi ts in Burn Surgery b Specifically Designed b ARTISS is indicated as a tissue glue to adhere/seal
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-7385407:2.0 Name of Sponsor/Company Grünenthal GmbH/Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name
More informationValue Assessment: Building Payercentric value propositions to inform decision-making
Value Assessment: Building Payercentric value propositions to inform decision-making Aris Angelis and Panos Kanavos Medical Technology Research Group, LSE Health Advance-HTA dissemination workshop, Santiago,
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationPraxbind. (idarucizumab) New Product Slideshow
Praxbind (idarucizumab) New Product Slideshow Introduction Brand name: Praxbind Generic name: Idarucizumab Pharmacological class: Humanized monoclonal antibody fragment Strength and Formulation: 2.5g/50mL;
More informationAntihemophilic Factor (Recombinant BDD) Fc Fusion Protein (Eloctate): Treatment Cost Comparison and Budget Impact Analysis
CADTH TECHNOLOGY REVIEW Antihemophilic Factor (Recombinant BDD) Fc Fusion Protein (): Treatment Cost Comparison and Budget Impact Analysis Product Line: Technology Review Version: 1.0 Issue Number: 2 Publication
More informationRecombinant Factor VII vs Cryoprecipitate. Dr. M. Truter Moderator: Prof. Pretorius
Recombinant Factor VII vs Cryoprecipitate Dr. M. Truter Moderator: Prof. Pretorius Discussion with Dr. J. Potgieter (Haematology) No articles on Recombinant factor VII vs Cryoprecipitate Different indications
More informationSign up to receive ATOTW weekly
RECOMBINANT HUMAN ACTIVATED PROTEIN C IN THE TREATMENT OF SEVERE SEPSIS ANAESTHESIA TUTORIAL OF THE WEEK 133 11 TH MAY 2009 Dr Richard Eve, Royal Cornwall Hospital, Cornwall, UK Correspondence to richardlloydeve@gmail.com
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationFrom the Western Vascular Society
From the Western Vascular Society A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures
More informationPREVELEAK Surgical sealant
PREVELEAK Surgical sealant Rx only Instructions for Use DEVICE DESCRIPTION PREVELEAK Surgical sealant (PREVELEAK) is a sealant developed to seal suture holes formed during surgical repair of the circulatory
More informationTapentadol immediate-release
New Medicines Profile July 2011 Issue No. 11/02 Tapentadol immediate-release Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Palexia (Grunenthal
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationThis paper reviews the potential cost-effectiveness
n reports n Cost-Effectiveness of Rivaroxaban After Total Hip or Total Knee Arthroplasty Louis M. Kwong, MD, FACS Abstract Venous thromboembolism (VTE) following joint replacement surgery represents an
More informationHemostasis Current Treatment Practices XX Country Country Report Qualitative Market Research
HealthQ International HemoStatis Current Treatment Practices Hemostasis Current Treatment Practices XX Country Country Report Qualitative Market Research Prepared for: Prepared by: HealthQ International
More informationFondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 969-974, 2016 Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis WEN JUN DONG, HUI JUAN QIAN,
More informationDirect anticoagulation therapy
Direct anticoagulation therapy Pan-Arab Meeting & Saudi Society of Hematology Dr Ihab Alhemaidi MBBS MRCP(Lond UK) FRCPath. Fellow of the Royal Society of Medicine Consultant Adult hematology/bmt Section
More informationEvaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study
Evaluation of AMG 531 Efficacy in Splenectomized Patients with Chronic ITP in a Randomized Placebo- Controlled Phase 3 Study Plenary Session at ASH 2007 Presented by Terry B. Gernsheimer Madeleine Verhovsek
More informationPiloting the National Cardiovascular Research Infrastructure: The SAFE-PCI for Women Trial
Piloting the National Cardiovascular Research Infrastructure: The SAFE-PCI for Women Trial Sunil V. Rao MD Associate Professor of Medicine Duke University Medical Center Duke Clinical Research Institute
More informationCLINICAL REPORTS HOW TO LEVERAGE PUBLISHED DATA EVALUATION
CLINICAL EVALUATION REPORTS HOW TO LEVERAGE PUBLISHED DATA If you are not a medical device company or do not have devices on the market in Europe, then comprehensive clinical evaluation reports may be
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationInvestigator Guide Reporting of Unanticipated Problems to the IRB
Committee for Protection of Human Subjects The IRB for New York Medical College, Westchester Medical Center, Metropolitan Hospital Center (HHC), and Westchester Institute for Human Development, Terence
More informationAlternative Haemostatic Agents in the Management of Obstetric Haemorrhage
Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Clinical Associate Professor Nolan McDonnell School of Medicine and Pharmacology, School of Women s and Infants Health University
More informationSources of Bias in Metaanalysis
Sources of Bias in Metaanalysis of RCTs Tarek A. Hammad, MD, PhD, MSc, MS, FISPE Executive Director, Epidemiology, Merck Research Laboratories Former Deputy Director of Epidemiology, OPE, OSE, CDER, FDA
More informationMark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada
Reversal of Enoxaparin-Induced Anticoagulation in Healthy Subjects by Andexanet Alfa (PRT064445), An Antidote for Direct and Indirect fxa Inhibitors A Phase 2 Randomized, Double-Blind, Placebo Controlled
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION FILGRASTIM (Grastofil Apotex Inc.) Indications: Prevention or Treatment of Neutropenia Recommendation: The CADTH Canadian Drug Expert Committee
More informationRECOMBINANT AND AUTOLOGOUS PLATELET-DERIVED GROWTH FACTORS AS A TREATMENT OF WOUND HEALING AND OTHER NON-ORTHOPEDIC CONDITIONS
CONDITIONS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationDeep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources
Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep Mark Crowther on behalf many Some slides modified from other sources 1 Disclosures Major disclosure: Paid consulting with Portola,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA
More informationJMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins
JMP FAMILY OF PRODUCTS: SOFTWARE FOR LIFE SCIENTISTS JMP JMP Pro JMP Genomics JMP Clinical JMP Add-Ins CLINICAL TRIAL DATA REVIEWS Randomized clinical trial remains the gold standard for evaluating efficacy
More informationHEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL
ONO PHARMACEUTICAL CO.,LTD. Corporate Communications Mail:public_relations@ono.co.jp March 2, 2015 HEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS (CARFILZOMIB) VERSUS VELCADE (BORTEZOMIB) MET PRIMARY ENDPOINT
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) GLATIRAMER ACETATE (GLATECT PENDOPHARM) Indication: Relapsing-Remitting Multiple Sclerosis RECOMMENDATION: The CADTH
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationCase studies in the design, analysis and interpretation of non-inferiority trials
Case studies in the design, analysis and interpretation of non-inferiority trials Krishan Singh, Ph.D. GlaxoSmithKline EFSPI Verona, Nov '08 1 Outline Introduction & Background Case Studies Altabax a topical
More informationDose Selection in Drug Development and Regulation: Possible Future Direction. Richard Lalonde and Donald Stanski Pfizer and AstraZeneca
Dose Selection in Drug Development and Regulation: Possible Future Direction Richard Lalonde and Donald Stanski Pfizer and AstraZeneca Overview What is the problem and how did we get here Examples of the
More informationWARNING LETTER. Dave Stack President and CEO Pacira Pharmaceuticals, Inc. 5 Sylvan Way Parsippany NJ 07054
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Dave Stack President and CEO 5 Sylvan Way Parsippany NJ 07054 RE:
More informationTrial-design in biosimilar research: Equivalence or non-inferiority design
Trial-design in biosimilar research: Equivalence or non-inferiority design Prof. Kit C.B. Roes Professor of Clinical Trial Methodology Advisor to MEB-CBG Overview The place(s) of the clinical efficacy
More informationModels of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics
Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 9/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TACHOSIL safely and effectively. See full prescribing information for TACHOSIL. TACHOSIL Fibrin Sealant
More information2014 CLINICAL POLICY UNIT. Dr Vesna Kupresan
2014 CLINICAL POLICY UNIT Dr Vesna Kupresan Healthcare Industry Challenges Medical inflation Cost drivers Aging population Increased utilization of healthcare Growing chronic disease burden Rapid evolution
More informationDOACs Can Be Reversed!
1 DOACs Can Be Reversed! AC Forum 14 th National Conference April 21, 2017 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures (last 12 months) Research support
More informationInnovative Clinical Development Solutions
Innovative Clinical Development Solutions From Protocol to Package Insert: A Data Journey AMWA Medical Writing & Communication Conference Thursday, November 1, 2018 Introductions Alex Rohall Senior Manager,
More informationD-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2
D-Stat Dry Topical Hemostat Proven to Reduce Time-to-Hemostasis 1,2 Clinical Data to Support a True Hemostat Results are from a 376-patient, five-center, prospective randomized U.S. clinical study evaluating
More informationRed Cell Transfusion LESSONS FROM TRAUMA
Red Cell Transfusion LESSONS FROM TRAUMA Sandro Rizoli, MD PhD FRCSC FACS Professor Surgery & Critical Care Medicine Trauma Program Director Chair Trauma Care Disclosure KCI Canada CSL Behring NovoNordisk
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationApplication supported by the Phase 3 MAIA study being reviewed under the FDA Real-Time Oncology Review pilot program
Media Inquiries: Satu Glawe Phone: +49 172 294 6264 Bernadette King Phone: 1-215-778-3027 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationANEMIA. Oral iron. IV iron gluconate (order set #233)
PREVENTION ANEMIA Oral iron IV iron gluconate (order set #233) TRANSEXAMIC ACID Efficacy of IV TXA in Reducing Blood Loss After Elective C-section: Prospective, Randomized, Double-blind, Placebo Controlled
More informationUse of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research Hospital in Turkey
VOLUME 8 NUMBER 3 September 2017 JOURNAL OF CLINICAL AND EXPERIMENTAL INVESTIGATIONS ORIGINAL ARTICLE Use of Heparin and The Related Incidence of Heparin- Induced Thrombocytopenia in an Education and Research
More informationAMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA
January 29, 2015 ONO PHARMACEUTICAL CO., LTD. Corporate Communications public_relations@ono.co.jp AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS Amgen (NASDAQ:AMGN) and its subsidiary Onyx
More informationargatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd
argatroban, 100mg/ml, concentrate for solution for infusion (Exembol) SMC No. (812/12) Mitsubishi Pharma Europe Ltd 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationVenous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle (randomization) 3.4 Trial monitoring: Interim decision and group sequential designs Bios 6648- pg 1 (a) Recruitment and
More informationCADTH Technology Report
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Technology Report Issue 138 July 2014 Human Fibrinogen Concentrate (RiaSTAP):
More informationThijs J Giezen, PharmD, MSc, PhD The Netherlands
Thijs J Giezen, PharmD, MSc, PhD The Netherlands Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, The Netherlands Member of the Biosimilar Medicinal Product Working Party of European
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE
More informationReverse the New Anticoagulants? Mitchell J Daley, PharmD, BCPS
Reverse the New Anticoagulants? Mitchell J Daley, PharmD, BCPS Clinical Pharmacy Specialist, Critical Care University Medical Center Brackenridge / Dell Seton Medical Center at the University of Texas
More informationClinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404
Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this
More informationAganirsen for pathological corneal neovascularisation
Aganirsen for pathological corneal neovascularisation August 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRole of fibrinogen concentrate in coagulation management in complex cardio-vascular surgery
Role of fibrinogen concentrate in coagulation management in complex cardio-vascular surgery Niels Rahe-Meyer Clinic for Anaesthesiology and Intensive Care Medicine In major blood loss, fibrinogen deficiency
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationAflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A12-19 Aflibercept (Eylea) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aflibercept (Eylea)
More informationNew Anticoagulants Linda Liu, M.D.
Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC
More informationDr. Andrew Kotaska YELLOWKNIFE NT 221 VENOUS THROMBOEMBOLISM PROPHYLAXIS: WHO REALLY NEEDS SNAKE OIL?
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 Dr. Andrew Kotaska YELLOWKNIFE NT 221 VENOUS THROMBOEMBOLISM PROPHYLAXIS:
More informationWhen to Stop Dose Escalation: MTD, MLD or?
When to Stop Dose Escalation: MTD, MLD or? Henri CAPLAIN First Joint Annual Meeting, AGAH Club Phase 1 STRASBOURG, France 1 So called MTD STOP FIM No MTD? 2 WHY WE NEED TO REACH THE MAXIMUM TOLERATED DOSE
More informationType of intervention Primary prevention. Economic study type Cost-effectiveness analysis.
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-07-1-0636 TITLE: Silver Foam Technologies Healing Research Program PRINCIPAL INVESTIGATOR: Michael F. Moore, M.D. CONTRACTING ORGANIZATION: Noble Biomaterials REPORT DATE: September
More informationBayer R&D Investor Day 2005
Science For A Better Life HealthCare Bayer R&D Investor 25 December 8, 25 London Bayer R&D Investor 25 BAY 59-7939: A Novel, ral, Direct Factor Xa Inhibitor Frank Misselwitz Head of Therapeutic Area Cardiovascular,
More informationCreation date: 02/02/2017 Effective date: 02/02/2017 Review date: - Modification: - 1 Introduction Changes List of Appendixes...
1 Introduction... 1 2 Changes... 1 3 List of Appendixes... 5 1 Introduction Changes to Sixth Edition Cell Therapy Standards and Accreditation Manual The table below outlines the made to the FACT-JACIE
More informationFinding the Evidence: Tools and Techniques for Literature Searching
Finding the Evidence: Tools and Techniques for Literature Searching April 24, 2015 Webinar for SHLA CADTH CADTH is an independent, not-for-profit producer and broker of health technology assessments. Federal,
More informationOverview of Reversal Agents in Development
Overview of Reversal Agents in Development Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee,National
More informationPLATELET GUIDANCE DOCUMENT
Government of Newfoundland and Labrador Department of Health and Community Services Provincial Blood Coordinating Program PLATELET GUIDANCE DOCUMENT Office of Administrative Responsibility Director, Regional
More informationFound: 30% of 25% eligible predicted by chart review; randomized: 28% of goal! Page 1
Is there evidence to mandate heparin prophylaxis in medical inpatients? Part 2 (Part 1: ACP/ASIM, Rochester MN, 10/30/09) Frank A. Lederle, MD Professor of Medicine VA, MN 55417 Recap of Part I. The problem
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014
pan-canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for Multiple Myeloma July 31, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationEverything You Wanted to Know About ClinicalTrials.gov*
Everything You Wanted to Know About * Deborah A. Zarin, MD Director, National Library of Medicine (*But Were Afraid to Ask) DISCLAIMER Views are mine and do not necessarily represent views of NIH or HHS
More informationBrain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
More informationAndrew Nesbitt, PhD. Disclaimer 10/10/2014. Determining the Immunogenicity of Biologics: a Tricky Problem. Employee of UCB ן
Determining the Immunogenicity of Biologics: a Tricky Problem Andrew Nesbitt, PhD UCB Director Cimzia PST Disclaimer 2 Employee of UCB The theories expressed in this presentation are the views of the speaker
More informationTissue Engineered Vascular Grafts
Tissue Engineered Vascular Grafts Jeffrey H. Lawson, M.D., Ph.D. Chief Medical Officer Humacyte Incorporated Professor of Surgery and Pathology Duke University Medical Center Disclosure Information Financial
More informationEileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA
Eileen Navarro MD, FACP Medical Officer, OCS, OTS, CDER, FDA 1 www.fda.gov WHAT MEDICAL REVIEWERS CAN DO WITH STANDARDIZED DATA AND METADATA RECEIVED IN MODULE 5 Eileen Navarro, MD, FACP OCS/OTS/CDER/FDA
More information12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab
12-Month Interim Analysis of APOE4 Carriers for Fixed and Titration Dosing Regimens in PRIME, a Phase 1b study of Aducanumab Vissia Viglietta, 1 John O Gorman, 1 Leslie Williams, 1 Tianle Chen, 1 Ahmed
More informationA Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 in Relapsed/Refractory Multiple Myeloma
1 von 5 10.12.2013 10:33 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: MOR202C101 Previous Study Return to List Next Study A Phase I/IIa Study of Human Anti-CD38 Antibody
More information